NYSE: CCMConcord Medical Services Holdings Ltd Stock
$4.44+0.25 (+5.97%)
Updated Mar 14, 2025
CCM Price
$4.44
Fair Value Price
N/A
Market Cap
$19.20M
52 Week Low
$3.82
52 Week High
$26.70
P/E
-0.36x
P/B
-0.06x
P/S
1.18x
PEG
N/A
Dividend Yield
N/A
Revenue
$35.52M
Earnings
-$73.74M
Gross Margin
470.1%
Operating Margin
-180.02%
Profit Margin
-211.7%
Debt to Equity
-2.2
Operating Cash Flow
N/A
Beta
0.13
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CCM Overview
Concord Medical Services Holdings Limited operates radiotherapy and diagnostic imaging centers in China offering electroencephalography for the diagnosis of epilepsy, thermotherapy to increase the efficacy of and for pain relief after radiotherapy and chemotherapy, high-intensity focused ultrasound therapy for the treatment of cancer, stereotactic radiofrequency ablation for the treatment of Parkinson's Disease, and refraction and tonometry for the diagnosis of ophthalmic conditions. Concord Medical Services was founded in 1997 and is headquartered in Beijing, China.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CCM's potential to beat the market
- CCM doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
B
CCM
RankedUnranked of 43
RankedUnranked of 43
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.72 | A | |
| $13.89 | A | |
| $24.05 | A |
Be the first to know about important CCM news, forecast changes, insider trades & much more!
CCM News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CCM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CCM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CCM is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
CCM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
There are 30 more CCM due diligence checks available for Premium users.
Valuation
CCM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.36x
Industry
14.13x
Market
3,446.61x
CCM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.06x
Industry
4.21x
CCM's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
CCM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$912.2M
Liabilities
$647.6M
Debt to equity
-2.2
CCM's short-term liabilities ($305.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CCM's long-term liabilities ($355.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CCM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CCM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
CCM vs Medical Care Facility Stocks
Concord Medical Services Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.